Clinical Trial Update: Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer

View source ↗

Summary

The document updates a clinical trial evaluating neoadjuvant dostarlimab for dMMR/MSI-H locally advanced rectal cancer and notes that the study is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• JEMPERLI (DOSTARLIMAB)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Locally Advanced Rectal Cancer (LARC) | Status: RECRUITING